Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 735 shares of the biopharmaceutical company’s stock after acquiring an additional 29 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $524,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after purchasing an additional 2,828 shares during the period. Golden State Equity Partners increased its position in shares of Regeneron Pharmaceuticals by 1,479.1% during the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 1,272 shares during the period. Fagan Associates Inc. increased its position in shares of Regeneron Pharmaceuticals by 42.2% during the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after purchasing an additional 3,832 shares during the period. ABC Arbitrage SA acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $1,510,000. Finally, Fisher Asset Management LLC increased its position in shares of Regeneron Pharmaceuticals by 16.5% during the 4th quarter. Fisher Asset Management LLC now owns 5,890 shares of the biopharmaceutical company’s stock valued at $4,197,000 after purchasing an additional 833 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $678.42 on Tuesday. The company has a market cap of $74.17 billion, a PE ratio of 17.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The stock has a 50-day moving average of $694.15 and a 200-day moving average of $827.65. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $11.86 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on REGN shares. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Bernstein Bank decreased their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.